Immunothérapie dans le cancer de la vessie : mise à jour 2021 [Immunotherapy for bladder cancer in 2021]

Metadatas

Authors
Date

May 19, 2021

types
Scope
Language
Identifiers
Source

Serveur académique Lausannois

Relations

This document is linked to :
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2021.17.739.0974

This document is linked to :
info:eu-repo/semantics/altIdentifier/pmid/34009756

This document is linked to :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379

This document is linked to :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_954186CA59D99

Collection

Serveur Académique Lausannois

Organization

Université de Lausanne et CHUV

Licenses

info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/

Keywords 0

Administration, Intravesical; BCG Vaccine; Humans; Immunologic Factors/therapeutic use; Immunotherapy; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms/drug therapy

Similar subjects Fr

Cancers Néoplasme malin Tumeurs malignes

Cite this document

C. Cisarovsky et al., « Immunothérapie dans le cancer de la vessie : mise à jour 2021 [Immunotherapy for bladder cancer in 2021] », Serveur académique Lausannois, ID : 10.53738/REVMED.2021.17.739.0974

Metrics

Share / Export

Abstract 0

Intravesical immunotherapy with Calmette-Guerin bacillus (BCG) have been used since decades for the treatment of non-muscle invasive bladder cancer and is a proof of principle that immunotherapy works for this malignancy. Since 2016, immune checkpoint inhibitors (ICI) demonstrated clinical benefits in locally advanced or metastatic bladder cancer, providing potentially durable tumor control in first line therapy or upon relapse after standard treatments. Ongoing clinical trials aim to demonstrate the efficiency of ICI for the treatment of localized disease.

document thumbnail

From the same authors

On the same subjects

Export in